Abstract |
Respiratory syncytial virus (RSV) pneumonia in BMT recipients carries a mortality rate of approximately 50-70% despite ribavirin ( Virazole) treatment. In both immunocompetent and immunocompromised animal models, RSV neutralizing antibodies rapidly reduce pulmonary virus load after a single dose. RSV-IGIV ( RespiGam) is an IgG immune globulin with high concentrations of RSV neutralizing antibody (>19 200 MU/ml). From June 1991 to February 1996, a compassionate-use protocol using RSV-IGIV for treatment of RSV infections was conducted. Eleven children at multiple centers, mean age 3.3 years (4 months to 9 years), were undergoing BMT and met the protocol criteria. They received a single 1500 mg/kg dose of RSV-IGIV infused over 12 h at a median of 5 days (1-37 days) after RSV symptom onset. Ten of these patients received prior or concurrent aerosolized ribavirin. Serum RSV neutralizing titers were measured in five patients and showed a 3- to 30-fold increase 24 h after RSV-IGIV infusion. Adverse events were mild. One of 11 (9.1%) patients died from their RSV illness (91% RSV survival). In comparison to previously published reports, RSV-IGIV treatment of RSV pneumonia in BMT patients may increase survival above that in such patients treated with ribavirin alone. Bone Marrow Transplantation (2000) 25, 161-165.
|
Authors | J P DeVincenzo, R L Hirsch, R J Fuentes, F H Top Jr |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 25
Issue 2
Pg. 161-5
(Jan 2000)
ISSN: 0268-3369 [Print] England |
PMID | 10673674
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Viral
- Antiviral Agents
- Immunoglobulins, Intravenous
- respiratory syncytial virus immune globulin intravenous
- Ribavirin
|
Topics |
- Administration, Inhalation
- Adult
- Antibodies, Viral
(blood)
- Antiviral Agents
(administration & dosage, therapeutic use)
- Bone Marrow Transplantation
(adverse effects, immunology)
- Child
- Child, Preschool
- Clinical Protocols
- Combined Modality Therapy
- Humans
- Immunoglobulins, Intravenous
(administration & dosage, adverse effects, immunology, therapeutic use)
- Immunosuppression Therapy
(adverse effects)
- Infant
- Neutralization Tests
- Pneumonia, Viral
(immunology, therapy)
- Respiratory Syncytial Virus Infections
(immunology, therapy)
- Respiratory Syncytial Viruses
(immunology, physiology)
- Ribavirin
(administration & dosage, therapeutic use)
- Survival Rate
- Viral Load
|